Director dealing

RNS Number : 0041C

Fusion Antibodies PLC

16 January 2018

 

16 January 2018

Fusion Antibodies plc 

("Fusion" or the "Company")

Director+ dealing

Fusion Antibodies (AIM: FAB), a contract research organization providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications, has been advised that Sonya Ferguson, Senior Independent Director of the Company, has acquired 15,593 ordinary shares of 4p each in the Company ("Ordinary Shares") at a price of 160p per share.  The Ordinary Shares were acquired through her SIPP.  Following this purchase, Sonya Ferguson now has a total beneficial interest in 15,593 Ordinary Shares, equivalent to 0.07% of the issued share capital.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Sonya Ferguson
2	Reason for the notification
a)	Position/status	Senior Independent Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Fusion Antibodies plc
b)	LEI	213800KBAYRC9VOQ9V39
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of £0.04 each in Fusion Antibodies plc  Identification code (ISIN) for Fusion Antibodies plc ordinary shares: GB00BDQZGK16
b)	Nature of the transaction	Purchase of shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 160p 15,593
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	15 January 2018
f)	Place of the transaction	London Stock Exchange, AIM (XLON)

The information set out in this announcement is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

Enquiries:

Fusion Antibodies plc		www.fusionantibodies.com
Dr Paul Kerr, Chief Executive Officer		Via Walbrook PR
James Fair, Chief Financial Officer
Allenby Capital Limited		Tel: [phone]
Virginia Bull / James Reeve / Asha Chotai
Walbrook PR	Tel: [phone] or [e-mail]
Paul McManus	Mob: [phone]
Anna Dunphy	Mob: [phone]

 

END

 

 

DSHSFFFSMFASESF